Signal from the log
Korsana Biosciences
175 M$ · Series A · United States · Biotech
Biotech de Waltham, dans le Massachusetts, qui développe des anticorps monoclonaux contre les maladies neurodégénératives à partir d'une plateforme de franchissement de la barrière hémato-encéphalique. Son candidat KRSA-028 vise la protéine bêta-amyloïde en injection sous-cutanée, avec une phase 1 attendue mi-2027.
Verified
Announced on , logged by the watch of 17 August 2026.
- Operation
- Funding round
- Announced amount
- 175 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Wellington Management , TCGX , with Fairmount , Venrock Healthcare Capital Partners , Paragon Therapeutics
Provenance
Source longevity
Logged on 17 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.